The exclusive agreement also includes development, regulatory, and commercialization milestone payments based on the successful outcome
Demonstrate significant bleed reduction in hemophilia A and B
New facility is part of Aptar Pharma’s global expansion program
This acquisition marks Max Healthcare's entry into Lucknow
Conditional marketing authorization is based on clinically meaningful response rates, duration of response, and safety from the Phase 2 MagnetisMM-3 trial
Approximately 16,000 patients 12 years of age and older with severe sickle cell disease may now be eligible for this one-time treatment
Express Scripts to add Zepbound to National Preferred Formulary
NATCO temporarily shut down the operations due to cyclone with flooding/water logging of the factory premises
The company is assessing the situation and simultaneously undertaking all the requisite action
Late-stage Fabhalta development program ongoing in multiple complement-mediated conditions
Subscribe To Our Newsletter & Stay Updated
